Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and clinical similarity study of MabionCD20 versus MabThera and Rituxan in rheumatoid arthritis
2020-002765-34Phase 3Terminated
- Sponsor
- Mabion S.A.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MabionCD20 and rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Mabion S.A. Primary endpoint: Co-primary PK endpoint 1. Started Aug 2021; status: terminated.
02
Drugs
MabionCD20rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2020-002765-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002765-34.